The success of ibrutinib (Imbruvica) has had a significant impact across several populations of patients with chronic lymphocytic leukemia (CLL). However, not all patients respond, and ibrutinib combinations and other novel regimens are being explored to improve outcomes, said Julio Chavez, MD.
on Hematologic Malignancies. In an interview at the meeting, he shared his insight on ibrutinib’s benefits and challenges, and emerging combinations in CLL.
OncLive: What did you focus on in your lecture on CLL?
CLL is the most common chronic leukemia in the United States. I focused on the new treatments available for this condition, including novel agents, and also on the efficacy and toxicity of potential combinations for future treatments on these patients.
What game-changing results have we seen with ibrutinib? Also, what do you do when patients fail on ibrutinib?
Ibrutinib has changed the landscape of treatment entirely for CLL. It is an oral agent that is generally well tolerated; however, there are some toxicities we should keep in mind, like increased bleeding, atrial fibrillation, or infections. Those are manageable, but we have to keep in mind that there are potential comorbidities.
... to read the full story